Serum Tryptase Levels During Cardiac Surgery, Diagnosis and Treatment Decisions for Allergic Reactions

Sponsor
Mustafa Kemal University (Other)
Overall Status
Completed
CT.gov ID
NCT02644785
Collaborator
(none)
30
1
1
29.5

Study Details

Study Description

Brief Summary

The investigators aim to assess tryptase test efficacy for measuring the allergic response to protamine during cardiac bypass surgery. Additionally, the investigators aim to establish a differential diagnosis on the basis of potential allergens or clinical causes.

Condition or Disease Intervention/Treatment Phase

Detailed Description

Venous blood samples from cardiac surgery cases will be obtained for tryptase measurement upon admission to the operating room (OR) and immediately prior to and 30 min after protamine infusion initiation. A rapid effect-response-based clinical assessment will be made using clinical and laboratory monitoring data for diagnosis and treatment decisions during protamine infusion, which may complicate the recovery from surgery.

Study Design

Study Type:
Observational
Actual Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Investigation of Anaphylactic Reaction in Cases Undergoing Cardiac By-Pass Surgery
Actual Study Start Date :
Jan 1, 2016
Actual Primary Completion Date :
Feb 1, 2016
Actual Study Completion Date :
Feb 1, 2016

Outcome Measures

Primary Outcome Measures

  1. Patients number with high tryptase level (> 25 µg/L ). [30 min]

    Tryptase will be measured using the ImmunoCAP Tryptase kit (Phadia, Uppsala, Sweden), and the cutoff level for elevated tryptase is >11.5 µg/L. A 25 µg/L cutoff value has been found to be highly suggestive of an İmmunoglobulin E (IgE) -mediated reaction.

Secondary Outcome Measures

  1. Patients number with allergic reaction involving of 1 or more organ/systems (skin, respiratory, or cardiovascular system) following the study drug infusion. In this study, mainly the cardiovascular and skin symptoms will be focused on. [30 min]

    These outcomes will be determined following the Council for International Organizations of Medical Sciences (CIOMS 1999 and ) definitions for anaphylactic reactions. Additionally, (World Health Organization - Uppsala Monitoring Centre) WHO-UMC system will be used for assesment of causality categories for adverse drug reactions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Cardiac by-pass cases
Exclusion Criteria:
  • Insulin dependent diabetes

  • Atopy

  • Drug allergy history

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mustafa Kemal University Hospital Hatay Turkey 31100

Sponsors and Collaborators

  • Mustafa Kemal University

Investigators

  • Principal Investigator: Menekse Oksar, M.D., Mustafa Kemal University Medical School

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
MENEKSE OKSAR, Assistant Professor, Mustafa Kemal University
ClinicalTrials.gov Identifier:
NCT02644785
Other Study ID Numbers:
  • 2014/10
First Posted:
Jan 1, 2016
Last Update Posted:
Mar 22, 2017
Last Verified:
Feb 1, 2016
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by MENEKSE OKSAR, Assistant Professor, Mustafa Kemal University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 22, 2017